Metabolism Considerations for Kinase Inhibitors in Cancer Treatment

Overview

Journal Expert Opin Drug Metab Toxicol

Publisher Informa Healthcare

Specialties Endocrinology
Pharmacology
Toxicology

Date 2010 Aug 6

PMID 20684746

Citations 43

Authors

Derek R Duckett

Michael D Cameron

Affiliations

Soon will be listed here.

Abstract

Importance Of The Field: A concerted effort by the pharmaceutical industry over the last decade has led to the successful clinical development of protein kinase inhibitors as effective targeted therapies for certain cancers.

Areas Covered In This Review: This review details eight small molecule kinase inhibitors that have been approved for the treatment of cancer in either the US or Europe as of March 2010: imatinib, sorafenib, gefitinib, erlotinib, dasatinib, lapatinib, sunitinib and nilotinib. These eight compounds vary from the relatively specific inhibitor lapatinib to the more promiscuous kinase inhibitors dasatinib and sunitinib.

What The Reader Will Gain: A brief discussion on the biology of each inhibitor, selectivity over other kinases and toxicity is provided. A more detailed discussion on the metabolism, drug transporters, drug-drug interactions and possible roles of metabolism in compound toxicity is provided for each compound.

Take Home Message: The majority of the currently approved kinase inhibitors is heavily influenced by drug transporters and significantly affected by CYP3A4 inhibitors/inducers. At least three, gefitinib, erlotinib and dasatinib, are metabolized to form reactive metabolites capable of covalently-binding biomolecules.

Citing Articles

Cellular and molecular aspects of drug resistance in cancers.

Shaik R, Malik M, Basavaraju S, Qurban J, Al-Subhi F, Badampudi S Daru. 2024; 33(1):4.

PMID: 39652186 PMC: 11628481. DOI: 10.1007/s40199-024-00545-8.

Targeting the EphA2 pathway: could it be the way for bone sarcomas?.

Giordano G, Tucciarello C, Merlini A, Cutrupi S, Pignochino Y Cell Commun Signal. 2024; 22(1):433.

PMID: 39252029 PMC: 11382444. DOI: 10.1186/s12964-024-01811-7.

Multiparametric MRI for characterization of the tumour microenvironment.

Hoffmann E, Masthoff M, Kunz W, Seidensticker M, Bobe S, Gerwing M Nat Rev Clin Oncol. 2024; 21(6):428-448.

PMID: 38641651 DOI: 10.1038/s41571-024-00891-1.

Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions.

Loer H, Kovar C, Rudesheim S, Marok F, Fuhr L, Selzer D CPT Pharmacometrics Syst Pharmacol. 2024; 13(6):926-940.

PMID: 38482980 PMC: 11179706. DOI: 10.1002/psp4.13127.

Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.

Latham B, Geffert R, Jackson K Drug Metab Dispos. 2024; 52(6):479-492.

PMID: 38286637 PMC: 11114602. DOI: 10.1124/dmd.123.001430.

References

Li J, Zhao M, He P, Hidalgo M, Baker S . Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007; 13(12):3731-7. DOI: 10.1158/1078-0432.CCR-07-0088. View

Gambacorti-Passerini C, Gasser M, Ahmed S, Assouline S, Scapozza L . Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia. 2005; 19(7):1267-9. DOI: 10.1038/sj.leu.2403775. View

Li X, Kamenecka T, Cameron M . Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol. 2009; 22(10):1736-42. DOI: 10.1021/tx900256y. View

Leggas M, Panetta J, Zhuang Y, Schuetz J, Johnston B, Bai F . Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res. 2006; 66(9):4802-7. DOI: 10.1158/0008-5472.CAN-05-2915. View

Marchetti S, de Vries N, Buckle T, Bolijn M, van Eijndhoven M, Beijnen J . Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008; 7(8):2280-7. DOI: 10.1158/1535-7163.MCT-07-2250. View

Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A . Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006; 12(24):7374-9. DOI: 10.1158/1078-0432.CCR-06-1516. View

Liu V, White D, Zakowski M, Travis W, Kris M, Ginsberg M . Pulmonary toxicity associated with erlotinib. Chest. 2007; 132(3):1042-4. DOI: 10.1378/chest.07-0050. View

Motzer R, Michaelson M, Rosenberg J, Bukowski R, Curti B, George D . Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007; 178(5):1883-7. DOI: 10.1016/j.juro.2007.07.030. View

Chou L, Garey J, Oishi K, Kim E . Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. Clin Lung Cancer. 2007; 8 Suppl 1:S15-22. DOI: 10.3816/clc.2006.s.009. View

10.

Li X, Kamenecka T, Cameron M . Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos. 2010; 38(7):1238-45. PMC: 3202369. DOI: 10.1124/dmd.109.030361. View

11.

Davies A, Jordanides N, Giannoudis A, Lucas C, Hatziieremia S, Harris R . Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009; 23(11):1999-2006. DOI: 10.1038/leu.2009.166. View

12.

Liu W, Makrauer F, Qamar A, Janne P, Odze R . Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol. 2007; 5(8):917-20. DOI: 10.1016/j.cgh.2007.04.014. View

13.

Kitajima H, Takahashi H, Harada K, Kanai A, Inomata S, Taniguchi H . Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers. Respirology. 2006; 11(2):217-20. DOI: 10.1111/j.1440-1843.2006.00835.x. View

14.

Crossman L, Druker B, Deininger M, Pirmohamed M, Wang L, Clark R . hOCT 1 and resistance to imatinib. Blood. 2005; 106(3):1133-4. DOI: 10.1182/blood-2005-02-0694. View

15.

Koch K, Beelen A, Ho P, Roychowdhury D . The value of label recommendations: how to dose lapatinib. J Clin Oncol. 2007; 25(33):5331-2. DOI: 10.1200/JCO.2007.13.8644. View

16.

Ling J, Johnson K, Miao Z, Rakhit A, Pantze M, Hamilton M . Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos. 2005; 34(3):420-6. DOI: 10.1124/dmd.105.007765. View

17.

Ramanarayanan J, Krishnan G . Review: hepatotoxicity and EGFR inhibition. Clin Adv Hematol Oncol. 2008; 6(3):200-1. View

18.

Su H, Seimbille Y, Ferl G, Bodenstein C, Fueger B, Kim K . Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008; 35(6):1089-99. DOI: 10.1007/s00259-007-0636-6. View

19.

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

20.

Dudek A, Kmak K, Koopmeiners J, Keshtgarpour M . Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer. 2005; 51(1):89-96. DOI: 10.1016/j.lungcan.2005.09.002. View